Five-year relapse-free survival and predictors of relapse following preoperative docetaxel and mitoxantrone for high-risk localized prostate cancer

被引：0
|
作者：
Rademacher, B. L.
Garzotto, M.
Higano, C. S.
O'Brien, C. A.
Janeba, N.
Fazli, L.
Lange, P. H.
Lieberman, S.
Beer, T. M.
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] OHSU, Portland VA Med Center, Portland, OR USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC, Canada
[5] Kaiser Permanente, Clackamas, OR USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5121
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer
    Barnett, Christine M.
    Heinrich, Michael C.
    Lim, Jeong
    Nelson, Dylan
    Beadling, Carol
    Warrick, Andrea
    Neff, Tanaya
    Higano, Celestia S.
    Garzotto, Mark
    Qian, David
    Corless, Christopher L.
    Thomas, George V.
    Beer, Tomasz M.
    [J]. CLINICAL CANCER RESEARCH, 2014, 20 (05) : 1306 - 1312
  • [2] The five-year relapse-free and overall survival following permanent 125 iodine prostate brachytherapy
    Morris, J.
    Keyes, M.
    McKenzie, M.
    Agronovitch, A.
    Spadinger, I.
    Harrison, B.
    Kwa, W.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2006, 80 : S42 - S42
  • [3] Predictors of early relapse in high risk prostate cancer patients treated with neoadjuvant mitoxantrone and docetaxel
    O'Brien, CA
    Garzotto, M
    Higano, CS
    Wersinger, EM
    Kaimaktchiev, V
    Corless, CL
    Lange, PH
    Ryan, CW
    Beer, TM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 412S - 412S
  • [4] Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer
    Garzotto, M
    Myrthue, A
    Higano, CS
    Beer, TM
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (03) : 254 - 259
  • [5] High-risk prostate cancer: comparison of 10 year biochemical relapse-free survival between high dose rate brachytherapy and open radical prostatectomy
    Savdie, R.
    Yuen, C.
    Haynes, A. M.
    Benito, R. Pe
    Rasiah, K.
    Jagavkar, R.
    Stricker, P.
    [J]. BJU INTERNATIONAL, 2010, 105 : 4 - 4
  • [6] Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy
    Joseph, J
    Al-Qaisieh, B
    Ash, D
    Bottomley, D
    Carey, B
    [J]. BJU INTERNATIONAL, 2004, 94 (09) : 1235 - 1238
  • [7] 15-year Biochemical Relapse-free Survival and Overall Survival following 125I Prostate Brachytherapy in Clinically Localized Prostate Cancer: Seattle Experience
    Sylvester, J. E.
    Grimm, P. D.
    Wong, J.
    Galbreath, R. W.
    Khanjian, J. A.
    Merrick, G. S.
    Blasko, J. C.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S326 - S327
  • [8] The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival
    Nguyen, Carvell T.
    Reuther, Alwyn M.
    Klein, Eric A.
    Jones, J. Stephen
    [J]. JOURNAL OF UROLOGY, 2008, 179 (04): : 55 - 55
  • [9] The Specific Definition of High Risk Prostate Cancer Has Minimal Impact on Biochemical Relapse-Free Survival
    Nguyen, Carvell T.
    Reuther, Alwyn M.
    Stephenson, Andrew J.
    Klein, Eric A.
    Jones, J. Stephen
    [J]. JOURNAL OF UROLOGY, 2009, 181 (01): : 75 - 80
  • [10] Phase 1/2 Study of Preoperative Docetaxel and Mitoxantrone for High-Risk Prostate Cancer
    Garzotto, Mark
    Higano, Celestia S.
    O'Brien, Catherine
    Rademacher, Brooks L. S.
    Janeba, Nicole
    Fazli, Ladan
    Lange, Paul H.
    Lieberman, Stephen
    Beer, Tomasz M.
    [J]. CANCER, 2010, 116 (07) : 1699 - 1708
12345